Eric Van Cutsem, MD, discusses a subgroup analysis involving patients 75 years of age and older in the Consign study of regorafenib for treatment-refractory metastatic colorectal cancer. The analysis found no major differences in safety compared with younger patients as long as the patients were fit enough to be eligible for treatment—so age itself is no reason to withhold regorafenib.
You are here
Robert A. Hromas, MD, Chair of the Department of Internal Medicine at the University of Florida College of Medicine, describes “very exciting” findings about venetoclax in treating chronic lymphocytic leukemia (CLL). The drug was very effective among hard-to-treat patients with the 17p deletion, and he believes it may hold promise for a range of other CLL patients as well.
Nicola Gökbuget, MD, of Goethe University in Frankfurt, Germany, discusses “very positive” results from trials of the bispecific T-cell engager blinatumomab in treating acute lymphocytic leukemia. Among 116 patients with high levels of minimal residual disease (MRD), 80% were found to be MRD-negative after just one cycle of treatment. Survival results were best if patients were treated in their first remission.
Rheumatologist Michael Weinblatt, MD, of Brigham and Women’s Hospital, discusses a post hoc analysis showing that rheumatoid arthritis patients’ response to certolizumab pegol and methotrexate after 12 weeks of treatment strongly predicts whether they’ll achieve sustained remission in the future with this regimen or should try other therapies.
Professor Chris Verslype, MD, PhD, an oncology/hepatology specialist in Belgium, discusses data that are raising interest in logoregional therapies for hepatocellular carcinoma and metastatic colon cancer. These options include PV-10, selective internal radiation therapy, and radiofrequency ablation.